SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…
Jörg Menten, previously acting as Chief Commercial Officer of the company, will focus on successfully commercializing the biomarker-based diagnostics that address high unmet needs in critical care…
New evidence supporting the use of innovative biomarkers in the early identification of organ dysfunction and risk stratification of cardiac surgery patients is reported.
SphingoTec and Rivaara Labs today announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec’s point of care diagnostic solutions in the Indian…
SphingoTec announces that its kidney function biomarker penKid is reliably identifying AKI in infants, offering a solution to the shortcomings in pediatric critical care. AKI is mostly diagnosed too…
SphingoTec announced the appointment of Jörg Menten as its Chief Commercial Officer. In this role, Menten will develop the global commercial strategy, oversee the expansion in diagnostic markets…
Open positions at SphingoTec
You are convinced that SphingoTec is the perfect employer for you? Then we are looking forward to receiving your application: We are constantly looking for highly…
Privacy policy for applicants
We would like to inform you about the collection and use of your personal data described here by participating in the application process. If required by applicable…
